Sheppard Mullin Richter & Hampton LLP | USA | 23 Jun 2022
On June 2, 2022, the US Food and Drug Administration (FDA) Office of Prescription Drug Promotion (OPDP) issued an untitled letter [1] to Althera…
McDermott Will & Emery | USA | 23 Jun 2022
The US Court of Appeals for the Fourth Circuit held that a corporation that is not physically present in a district is not “found” in the district…
EIP | European Union, United Kingdom | 7 Jun 2022
Swiss drug-maker, Novartis, sought a preliminary injunction to keep Teva and four other generics off the market for its prescription-only relapse…
Rouse | China | 2 May 2022
In this report we focus on trade secret litigation in China. We examine a selection of published trade secret cases in our CIELA database from the…
Sheppard Mullin Richter & Hampton LLP | USA | 19 Apr 2022
On March 31, 2022, the Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) issued an untitled letter to…
NLO | European Union, Netherlands | 15 Apr 2022
In 2017 an article appeared by Kleemans and Drok about the interpretation of Swiss-type claims and EPC-2000 claims. In this article, they discuss the…
McDermott Will & Emery | France | 24 Mar 2022
CA Paris, 9 novembre 2021, aff. Eli Lilly c. Zentiva France (n°RG 21/01880) La Cour d'appel de Paris confirme l'injonction préliminaire…
McDermott Will & Emery | France | 23 Mar 2022
CA Paris, November 9, 2021, Eli Lilly v. Zentiva France (Docket No. 21/01880) The Paris Court of Appeal upheld a preliminary injunction prohibiting…
Morrison & Foerster LLP | USA | 9 Mar 2022
On February 10, 2022, the U.S. Food and Drug Administration (FDA) held a public Oncologic Drugs Advisory Committee (ODAC) meeting to discuss the…
Covington & Burling LLP | USA | 17 Feb 2022
This e-alert reviews trends emerging from Warning Letters and untitled letters concerning product advertising and promotion issued in 2021 by the…